Mc-MMAD

HY-15740				
1401963-15-2				
C ₅₁ H ₇₇ N ₇ O ₉ S				
964.26	Survey of the state of the stat			
Microtubule/Tubulin; Drug-Linker Conjugates for ADC				
Cell Cycle/DNA Damage; Cytoskeleton; Antibody-drug Conjugate/ADC Related				
Powder -20°C 3 years 4°C 2 years * The compound is unstable in solutions, freshly prepared is recommended				
	1401963-15-2 C ₅₁ H ₇₇ N ₇ O ₉ S 964.26 Microtubule/Tubulin; Drug-Linker Conjugates for ADC Cell Cycle/DNA Damage; Cytoskeleton; Antibody-drug Conjugate/ADC Related Powder -20°C 3 years			

SOLVENT & SOLUBILITY

	Preparing Stock Solutions	Mass Solvent Concentration	1 mg	5 mg	10 mg
		1 mM	1.0371 mL	5.1853 mL	10.3706 mL
		5 mM	0.2074 mL	1.0371 mL	2.0741 mL
		10 mM	0.1037 mL	0.5185 mL	1.0371 mL
	Please refer to the sol	ubility information to select the app	propriate solvent.		
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (2.59 mM); Clear solution				
		ne by one: 10% DMSO >> 90% cor ;/mL (2.59 mM); Clear solution	n oil		

BIOLOGICAL ACTIVITY			
Description	Mc-MMAD is a protective group (maleimidocaproyl)-conjugated MMAD. MMAD is a potent tubulin inhibitor. Mc-MMAD is a agent-linker conjugate for ADC.		
IC ₅₀ & Target	Auristatin		

REFERENCES

[1]. Antibody-drug conjugates Patent: WO 2013068874 A1

Product Data Sheet



Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA